Access to reimbursement for
orphan medicinal products is subject to specific legislative procedures.
However, the procedural pathway chosen by the marketing authorisation holder
(MAH) fundamentally determines which criteria will be assessed when evaluating
clinical benefit and economic effectiveness. This is illustrated by a
comparison of two administrative proceedings concerning the same...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
